Though it is estimated that about 5 percent of patients with pancreatic cancer are BRCA carriers, this subset of individuals may be more responsive to therapies that damage DNA, such as some chemotherapies, radiation therapy and some targeted therapies. As a result, BRCA carriers with pancreatic cancer may live longer than their counterparts who do not carry the mutation. Read more . . .